Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 18;6(1):2055217320906844. doi: 10.1177/2055217320906844

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 5. — Treatment effect of fingolimod 0.5 mg on the occurrence of NE lesions by location. In each brain region and in the whole brain, the effect of fingolimod on lesion formation was investigated using a negative binomial in which the new/enlarging lesion number was the dependent variable and treatment, clinical trial and baseline lesion number were the independent variables. The LRR between the fingolimod-treated and placebo patients was calculated, as were the CIs. The treatment effect of fingolimod versus placebo (% change) on the number of new or enlarging lesions was calculated as (LRR-1)*100 and is reported on the right side of the plot (a negative number favours fingolimod), together with the p value level (i.e. p > 0.1; . 0.1 ≤ p < 0.05; *0.05 ≤ p < 0.01; **0.01 ≤ p < 0.001; ***p ≤ 0.001). BR: supratentorial brain; BS: brainstem; CI: confidence interval; CR: cerebellum; LRR: lesion rate ratio; NE: new/enlarging.